Precision Epigenomics Announces Unprecedented Early-Stage Sensitivity Data for EPISEEK Multi-Cancer Early Detection Test
TUCSON, AZ, UNITED STATES, September 1, 2026 /EINPresswire.com/ -- Precision Epigenomics today announced new clinical
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
TUCSON, AZ, UNITED STATES, September 1, 2026 /EINPresswire.com/ — Precision Epigenomics today announced new clinical validation data for its EPISEEK® test, an advanced Multi-Cancer Early Detection (MCED) liquid biopsy. The findings highlight EPISEEK’s superior sensitivity in early-stage cancer detection and its unique capability to identify the most aggressive malignancies lacking standard screening options.
EPISEEK® Demonstrates Superior Early-Stage Sensitivity
The detailed performance metrics are based on an incidence-adjusted model analyzing 380 plasma samples across various cancer types and stages using SEER cancer incidence data.
Targeted Efficacy: EPISEEK achieved an incidence-adjusted estimated sensitivity of 72% across all stages for aggressive target cancers, which include lung, pancreas, liver, uterus, esophagus, bladder, oropharynx, and stomach cancers.
Early Detection Focus: For all Stage I-II cancers, observed sensitivity reached 58%, roughly 75% better than its closest competitor.
Broad Coverage: The platform detects over 60 cancer types (ICD-O-3), showing high observed sensitivities in historically difficult-to-detect forms like stomach, hematologic, and esophageal cancers. EPISEEK is the only MCED test shown to detect brain cancer (72%).
“From a clinical perspective, what sets EPISEEK apart is its unprecedented ability to identify aggressive, highly fatal malignancies that have historically lacked standard screening options,” said Dr. Richard Bernert, Chief Medical Officer and COO of Precision Epigenomics. “Achieving a 64% incidence-adjusted sensitivity for early Stage I and II target cancers—and successfully detecting low- and high-grade cancers of the brain where alternative platforms fall short—represents a monumental leap forward. We are giving physicians a reliable tool to catch the most dangerous cancers when they are most treatable.”
Superiority Over Current Market Alternatives
Unlike other tests in the market relying on complex Next-Generation Sequencing (NGS) or combined NGS and protein analysis, EPISEEK® utilizes a streamlined qPCR technology. This approach allows for faster, more cost-effective, and highly precise diagnostics.
EPISEEK maintains a robust 65% Positive Predictive Value (PPV) and 99.5% Negative Predictive Value (NPV), grounded in an overall specificity of 99.5%. Notably, it achieved 72% sensitivity in brain cancer, compared to 0% reported by alternative platforms in case control studies.
“We founded Precision Epigenomics with the conviction that early cancer detection must be both highly sensitive and highly accessible,” said Mark Nelson, PhD, CEO of Precision Epigenomics. “The data demonstrating EPISEEK’s 58% observed sensitivity in Stages I and II, coupled with a turnaround time of just one week and an affordable price point, proves that our streamlined qPCR technology is breaking down the barrier to early intervention. We are delivering a faster, more cost-effective solution without compromising on the precision that patients and providers deserve.”
EPISEEK is available to order online as well as through the physician network. For more information, please email info@precision-epigenomics.com.
Precision Epigenomics is an innovative molecular diagnostics company dedicated to transforming clinical oncology. By identifying precise epigenomic modifications from a standard blood draw, EPISEEK® provides accessible, actionable early cancer detection.
Precision Epigenomics EPISEEK Multi-Cancer Early Detection Test Overview
This video provides a brief, visual overview of how the EPISEEK test utilizes epigenomics to offer accessible, non-invasive early cancer detection for patients.
Regulatory and Forward-Looking Statements Disclaimer
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements included, but are not limited to product performance and the anticipated benefits of the EPISEEK-MCED test. Forward looking statements are based on current assumptions and are subject to change that may cause actual results to differ materially from those expressed or implied. These risks include, among others, regulatory developments, competitive pressures, operational challenges, and economic conditions.
The EPISEEK-MCED test is not intended to diagnose, treat, or cure any disease and should be used in conjunction with other clinical evaluations. Statements regarding clinical utility, performance, or outcomes have not been evaluated by the U.S. Food and Drug Administration unless otherwise stated. Precision Epigenomics undertakes no obligation to update forward-looking statements except as required by law.
Richard Bernert
Precision Epigenomics Inc.
+1 520-372-7522
email us here
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
